Cargando…

P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers

Detalles Bibliográficos
Autores principales:	Aboud, S, Mhalu, F, Bakari, M, Lifson, J, Lyamuya, E, Marovich, M, Cox, J, Sandstrom, E, Biberfeld, G, Nilsson, C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767683/ http://dx.doi.org/10.1186/1742-4690-6-S3-P191

Ejemplares similares

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
por: Joachim, Agricola, et al.
Publicado: (2015)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
por: Joachim, Agricola, et al.
Publicado: (2020)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

Experiences of Social Harm and Changes in Sexual Practices among Volunteers Who Had Completed a Phase I/II HIV Vaccine Trial Employing HIV-1 DNA Priming and HIV-1 MVA Boosting in Dar es Salaam, Tanzania
por: Tarimo, Edith A. M., et al.
Publicado: (2014)

Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial
por: Bakari, Muhammad, et al.
Publicado: (2013)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
por: Joachim, Agricola, et al.
Publicado: (2020)

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
por: Munseri, Patricia. J., et al.
Publicado: (2015)

The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers—A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania
por: Faini, Diana, et al.
Publicado: (2022)

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
por: Msafiri, Frank, et al.
Publicado: (2020)

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
por: Jaoko, Walter, et al.
Publicado: (2010)

Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam
por: Ngatoluwa, M, et al.
Publicado: (2012)

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
por: Joachim, Agricola, et al.
Publicado: (2016)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
por: Currier, Jeffrey R., et al.
Publicado: (2010)

A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania
por: Tarimo, Edith AM, et al.
Publicado: (2011)

DNA ploidy, cell proliferation, and HIV/EBV association in Tanzanian malignant lymphomas
por: Mwakigonja, Amos, et al.
Publicado: (2010)

Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association
por: Mwakigonja, Amos R, et al.
Publicado: (2010)

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation
por: Bråve, Andreas, et al.
Publicado: (2010)

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial
por: Currier, JR, et al.
Publicado: (2009)

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial
por: Nilsson, Charlotta, et al.
Publicado: (2015)

Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania
por: Tarimo, Edith A. M., et al.
Publicado: (2018)

A multiclade DNA/Ad vaccines for AIDS: the present and next generation
por: Nabel, Gary J
Publicado: (2006)

Vitamin D and HIV Progression among Tanzanian Adults Initiating Antiretroviral Therapy
por: Sudfeld, Christopher R., et al.
Publicado: (2012)

Declining HIV-1 prevalence and incidence among Police Officers – a potential cohort for HIV vaccine trials, in Dar es Salaam, Tanzania
por: Munseri, Patricia J, et al.
Publicado: (2013)

Supplementation With Multivitamins and Vitamin A and Incidence of Malaria Among HIV-Infected Tanzanian Women
por: Olofin, Ibironke O., et al.
Publicado: (2014)

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

Risk Factors for Preterm Birth among HIV-Infected Tanzanian Women: A Prospective Study
por: Zack, Rachel M., et al.
Publicado: (2014)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania
por: Tarimo, E. A. M., et al.
Publicado: (2016)

Predictors of stunting, wasting, and underweight among Tanzanian children born to HIV-infected women
por: McDonald, Christine M., et al.
Publicado: (2012)

Reasons for Declining to Enroll in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, Tanzania
por: Tarimo, Edith A. M., et al.
Publicado: (2011)

Correlates of HIV-1 Genital Shedding in Tanzanian Women
por: Tanton, Clare, et al.
Publicado: (2011)

Advanced baseline immunosuppression is associated with elevated levels of plasma markers of fungal translocation and inflammation in long-term treated HIV-infected Tanzanians
por: Barabona, Godfrey, et al.
Publicado: (2021)

Enumeration of CD4(+) T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients
por: Moon, SangJun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_durve2sk4efguu4kvp7ei8mbtm